cnio INNOVATION

PROTEIN KINASE INHIBITORS

The CNIO has developed compounds useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. CDK8 and/or Haspin kinase) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

Industrial partners are being sougth to collaborate through a patent license agreement for the development and exploitation of the technology

Description

The Experimental Therapeutics Programme from the CNIO has developed novel pharmaceutically-useful compounds, useful as kinase inhibitors (such as inhibitors of the CDK8 and/or Haspin kinases). The compounds are of potential utility in the treatment of diseases such as cancer, particularly colorectal/colon cancer, breast cancer, pancreatic cancer and cervical cancer.

Main innovations and advantages

The compounds of the present invention provide selective targeted therapies which provide advantages over current anti-cancer treatments, for example by reducing side effects (e.g. by preventing the killing of normal cells, as may occur using e.g. chemotherapy).



Intelectual property

Patent title :

"Condensed tricyclic compounds as protein kinase inhibitors"

Applicant: Spanish National Cancer Research Center (CNIO)

International patent application no: WO2017033019 (A1)

Patent granted in: Australia, China, Europe, India, Israel, Japan and USA.

For more information, please contact:

Technology Transfer and Valorization Office
Centro Nacional de Investigaciones Oncológicas
C/ Melchor Fernández Almagro, 3
28029 Madrid Spain
technologytransfer@cnio.es
www.cnio.es
@CNIO_Cancer